• Foundation Medicine plans to launch FoundationOne PGx, expanding its oncology portfolio into pharmacogenetic testing through an expanded partnership with Fulgent Genetics.
• US rollout will run through Fulgent’s platform with ordering routed through Foundation’s portal, positioning the product for faster commercial uptake in routine oncology workflows.
• Offering targets earlier, proactive use to help clinicians manage therapy selection and dosing decisions, supporting differentiation as oncology care shifts toward broader genomic-informed treatment planning.
• Move strengthens competitive positioning against precision-medicine peers by pairing pharmacogenetics with comprehensive genomic profiling to increase clinical touchpoints across a patient’s care pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.